Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model

References

• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint clockade: A common denominator approach to cancer therapy. Cancer Cell. 2015;27:450-61. https://doi.org/10.1016/j.ccell.2015.03.001. PMID:25858804
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23. https://doi.org/10.1056/NEJMoa1003466. PMID:20525992
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134-44. https://doi.org/10.1056/NEJMoa1305133. PMID:23724846
   PubMed Web of Science ®Google Scholar
• Fecci PE, Heimberger AB, Sampson JH. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res. 2014;20:5620-9. https://doi.org/10.1158/1078-0432.CCR-14-0832. PMID:25398845
   PubMed Web of Science ®Google Scholar
• Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science. 1997;278:1626-9. https://doi.org/10.1126/science.278.5343.1626. PMID:9374463
   PubMed Web of Science ®Google Scholar
• Hunn MK, Farrand KJ, Broadley KW, Weinkove R, Ferguson P, Miller RJ, Field CS, Petersen T, McConnell MJ, Hermans IF. Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma. Clin Cancer Res. 2012;18:6446-59. https://doi.org/10.1158/1078-0432.CCR-12-0704. PMID:23147997
   PubMed Web of Science ®Google Scholar
• Kruser TJ, Mehta MP, Robins HI. Pseudoprogression after glioma therapy: a comprehensive review. Expert Rev Neurotherapeutics. 2013;13:389-403. https://doi.org/10.1586/ern.13.7
   PubMed Web of Science ®Google Scholar
• Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332:600-3. https://doi.org/10.1126/science.1202947. PMID:21474713
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459-65. https://doi.org/10.1084/jem.182.2.459. PMID:7543139
   PubMed Web of Science ®Google Scholar
• Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541-7. https://doi.org/10.1016/1074-7613(95)90125-6. PMID:7584144
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncology. 2015;33:1974-82. https://doi.org/10.1200/JCO.2014.59.4358
   PubMed Web of Science ®Google Scholar
• Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210:1695-710. https://doi.org/10.1084/jem.20130579. PMID:23897981
   PubMed Web of Science ®Google Scholar
• Engelhardt B. Molecular mechanisms involved in T cell migration across the blood-brain barrier. J Neural Transmission. 2006;113:477-85. https://doi.org/10.1007/s00702-005-0409-y
   PubMed Web of Science ®Google Scholar
• Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207:637-50. https://doi.org/10.1084/jem.20091918. PMID:20156971
   PubMed Web of Science ®Google Scholar
• Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry WT, Jr. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother. 2012;35:385-9. https://doi.org/10.1097/CJI.0b013e3182562d59. PMID:22576343
   PubMed Web of Science ®Google Scholar
• Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res. 2007;13:2158-67. https://doi.org/10.1158/1078-0432.CCR-06-2070. PMID:17404100
   PubMed Web of Science ®Google Scholar
• Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373-7. https://doi.org/10.1038/nature14292. PMID:25754329
   PubMed Web of Science ®Google Scholar
• Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, Solomon S, Dong Z, Wong P, Comstock C, et al. Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. Cancer Immunol Res. 2016;4:835-44. https://doi.org/10.1158/2326-6066.CIR-16-0013. PMID:27587469
   PubMed Web of Science ®Google Scholar
• Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624. https://doi.org/10.1038/ncomms12624. PMID:27571927
   PubMed Web of Science ®Google Scholar
• Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, Gottschalk C, Nicholas S, Kellett M, Ruzevick J, Jackson C, et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PloS one. 2014;9:e101764. https://doi.org/10.1371/journal.pone.0101764. PMID:25013914
   PubMed Web of Science ®Google Scholar
• Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res. 2016;4:124-35. https://doi.org/10.1158/2326-6066.CIR-15-0151.
   Web of Science ®Google Scholar
• Vom Berg J, Vrohlings M, Haller S, Haimovici A, Kulig P, Sledzinska A, Weller M, Becher B. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J Exp Med. 2013;210:2803-11. https://doi.org/10.1084/jem.20130678. PMID:24277150
   PubMed Web of Science ®Google Scholar
• Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, Cheng Y, Kim JW, Qiao J, Zhang L, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014;20:5290-301. https://doi.org/10.1158/1078-0432.CCR-14-0514. PMID:24691018
   PubMed Web of Science ®Google Scholar
• Chen YH, Chiu NM, Mandal M, Wang N, Wang CR. Impaired NK1+ T cell development and early IL-4 production in CD1-deficient mice. Immunity. 1997;6:459-67. https://doi.org/10.1016/S1074-7613(00)80289-7. PMID:9133425
   PubMed Web of Science ®Google Scholar
• Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol. 1998;76:34-40. https://doi.org/10.1046/j.1440-1711.1998.00709.x. PMID:9553774
   PubMed Web of Science ®Google Scholar
• Kontgen F, Suss G, Stewart C, Steinmetz M, Bluethmann H. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Int Immunol. 1993;5:957-64. https://doi.org/10.1093/intimm/5.8.957. PMID:8398989
   PubMed Web of Science ®Google Scholar
• Van Kaer L, Ashton-Rickardt PG, Ploegh HL, Tonegawa S. TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4−8+ T cells. Cell. 1992;71:1205-14. https://doi.org/10.1016/S0092-8674(05)80068-6. PMID:1473153
   PubMed Web of Science ®Google Scholar
• Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science. 1993;259:1739-42. https://doi.org/10.1126/science.8456300. PMID:8456300
   PubMed Web of Science ®Google Scholar
• Lee A, Farrand KJ, Dickgreber N, Hayman CM, Jurs S, Hermans IF, Painter GF. Novel synthesis of alpha-galactosyl-ceramides and confirmation of their powerful NKT cell agonist activity. Carbohydr Res. 2006;341:2785-98. https://doi.org/10.1016/j.carres.2006.09.006. PMID:17014832
   PubMed Web of Science ®Google Scholar
• Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, Riddell SR, Warren EH, Carlson CS. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009;114:4099-107. https://doi.org/10.1182/blood-2009-04-217604. PMID:19706884
   PubMed Web of Science ®Google Scholar
• Carlson CS, Emerson RO, Sherwood AM, Desmarais C, Chung MW, Parsons JM, Steen MS, LaMadrid-Herrmannsfeldt MA, Williamson DW, Livingston RJ, et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun. 2013;4:2680. https://doi.org/10.1038/ncomms3680. PMID:24157944
   PubMed Web of Science ®Google Scholar